Trial Profile
Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2024
Price :
$35
*
At a glance
- Drugs Ecopipam (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Acronyms D1AMOND
- Sponsors Emalex Biosciences
- 01 Apr 2024 According to a Paragon Biosciences media release, the data from this trial will be presented at the at the AAN Annual Meeting, 2024.
- 27 Apr 2023 Results of a PopPK model analysis using data from this trial presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 11 Jan 2023 According to an Emalex Biosciences media release, data of this study published in the journal Pediatrics.